Purpose: Synchrotron Microbeam Radiation Therapy (MRT) is a pre-clinical modality characterised by spatial dose fractionation on a microscopic scale. Treatment planning studies using clinical datasets have not yet been conducted. Our aim was to investigate MRT dose-distributions in scenarios refractory to conventional treatment and to identify optimal settings for a future Phase I trial.
Methods: MRT plans were generated for seven scenarios where re-irradiation was performed clinically. A hybrid algorithm, combining Monte Carlo and convolution-based methods, was used for dose-calculation. The valley dose to organs at risk had to respect the single fraction tolerance doses achieved in the corresponding re-irradiation plans. The resultant peak dose and the peak-to-valley dose ratio (PVDR) at the tumour target volume were assessed.
Results: Peak doses greater than 80 Gy in a single fraction, and PVDRs greater than 10, could be achieved for plans with small (<35 cm3) or shallow volumes, particularly recurrent glioblastoma, head and neck tumours, and select loco-regionally recurrent breast cancer sites. Treatment volume was a more important factor than treatment depth in determining the PVDR. The mean PVDR correlated strongly with the size of the target volume (rs = -0.70, p = 0.01). The PVDRs achieved in these clinical scenarios are considerably lower than those reported in previous pre-clinical studies.
Conclusion: Our findings suggest that head and neck sites will be optimal scenarios for MRT.
Keywords: Microbeams; Synchrotron X-rays; Treatment planning.
Copyright © 2019 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.